Methods of treating cancer
AssigneeFoghorn Therapeutics Inc.
InventorsHo Man CHAN, Qianhe ZHOU, Luis SOARES
Life of this patent
Estimating the term…
Abstract
The present disclosure features useful methods to treat cancer having a deficiency in ARID1 A and/or mismatch repair deficiency, e.g., in a subject in need thereof. In some embodiments, the methods described herein are useful in the treatment of cancer in combination with immunotherapies.
Claims34
A method of treating cancer having a mutation that results in a loss of function of AT-Rich Interaction Domain 1A (ARID1A) in a subject in need thereof, the method comprising administering to the subject an effective amount of an agent that reduces the level and/or activity of Werner Syndrome RecQ Like Helicase (WRN) in a cell in the subject.
A method of reducing the level and/or activity of WRN in a cancer cell having a mutation that results in a loss of function of ARID1A in a subject, the method comprising contacting the cell with an effective amount of an agent that reduces the level and/or activity of WRN in the cell.
A method of reducing tumor growth of a cancer having a mutation that results in a loss of function of ARID1A in a subject, the method comprising administering to the subject an effective amount of an agent that reduces the level and/or activity of WRN in a cell in the subject.
A method of treating cancer having a mismatch repair deficiency (MMRd) in a subject in need thereof, the method comprising administering to the subject an effective amount of an agent that reduces the level and/or activity of WRN in a cell in the subject.
A method of reducing the level and/or activity of WRN in a cancer cell having a MMRd in a subject, the method comprising contacting the cell with an effective amount of an agent that reduces the level and/or activity of WRN in the cell.
A method of reducing tumor growth of a cancer having a MMRd in a subject in need thereof, the method comprising administering to the subject an effective amount of an agent that reduces the level and/or activity of WRN in a cell in the subject.
A method of treating cancer having a microsatellite instability (MSI)-positive phenotype in a subject in need thereof, the method comprising administering to the subject an effective amount of an agent that reduces the level and/or activity of WRN in a cell in the subject.
A method of reducing the level and/or activity of WRN in cancer cell having an MSI-positive phenotype in a subject, the method comprising contacting the cell with an effective amount of an agent that reduces the level and/or activity of WRN in the cell.
A method of reducing tumor growth of a cancer having an MSI-positive phenotype in a subject in need thereof, the method comprising administering to the subject an effective amount of an agent that reduces the level and/or activity of WRN in a cell in the subject.
Dependencies are inferred from the claim text.